Payment overview · 2025
General Payments
$1,145.73
63 reported records · 16 companies
Healthcare provider profile · identity verified
Jeremy Patrick Holter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHAWNEE, OK · NPI 1003859778
Verified facts
What the public records show
CMS Open Payments records show Jeremy Patrick Holter, MD received $1,145.73 in general payments during 2025 across 63 reported records.
ABBVIE INC. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $241.76 | 21.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.69 | 18.6% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $127.37 | 11.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.08 | 9.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.99 | 7.4% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.21 | 6.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.20 | 4.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.81 | 4.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.09 | 4.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $37.09 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.38 | 2.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.36 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.58 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.42 | 1.5% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $15.41 | 1.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.29 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,145.73 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $199.73 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $127.37 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $116.25 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.82 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.17 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.01 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.01 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.21 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.20 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.81 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.81 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.11 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.38 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 75 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
61 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
47 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 108 |
| Losartan Potassium | Losartan Potassium | 416 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 94 |
| Montelukast Sodium | Montelukast Sodium | 372 | 99 |
| Meloxicam | Meloxicam | 290 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 289 | 70 |
| Omeprazole | Omeprazole | 268 | 64 |
| Gabapentin | Gabapentin | 262 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 53 |
| Furosemide | Furosemide | 184 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 168 | 45 |
| Metformin Hcl | Metformin Hcl | 164 | 44 |
| Carvedilol | Carvedilol | 155 | 35 |
| Alendronate Sodium | Alendronate Sodium | 145 | 29 |
| Trazodone Hcl | Trazodone Hcl | 139 | 32 |
| Potassium Chloride | Potassium Chloride | 135 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 29 |
| Celecoxib | Celecoxib | 122 | 32 |
| Ozempic | Semaglutide | 118 | 24 |
| Pregabalin | Pregabalin | 117 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 113 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 33 |
| Allopurinol | Allopurinol | 107 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 35 |
| Lisinopril | Lisinopril | 106 | 30 |
| Ramipril | Ramipril | 106 | 23 |
| Simvastatin | Simvastatin | 99 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 33 |
| Glipizide | Glipizide | 85 | 23 |
| Methylprednisolone | Methylprednisolone | 77 | 65 |
| Famotidine | Famotidine | 76 | 31 |
| Eliquis | Apixaban | 75 | 14 |
| Synthroid | Levothyroxine Sodium | 70 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 24 |
| Tramadol Hcl | Tramadol Hcl | 69 | 28 |
| Colestipol Hcl | Colestipol Hcl | 64 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 61 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 15 |
| Ezetimibe | Ezetimibe | 56 | 14 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 13 |
| Ibuprofen | Ibuprofen | 47 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 36 |
| Spironolactone | Spironolactone | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Azithromycin | Azithromycin | 42 | 34 |
| Prednisone | Prednisone | 41 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Nystatin | Nystatin | 39 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Azelastine Hcl | Azelastine Hcl | 31 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | 17 |
| Baclofen | Baclofen | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Topiramate | Topiramate | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,145.73 · 63 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Saxenda, TRELEGY ELLIPTA, TRINTELLIX, TRUMENBA, UBRELVY, VRAYLAR, Wegovy, XYOSTED, Xelstrym, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error